Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Change in Accured Expenses (2019 - 2025)

Summit Therapeutics (SMMT) has disclosed Change in Accured Expenses for 7 consecutive years, with $14.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 513.3% year-over-year to $14.0 million, compared with a TTM value of $12.9 million through Dec 2025, up 8.85%, and an annual FY2025 reading of $12.9 million, up 8.85% over the prior year.
  • Change in Accured Expenses was $14.0 million for Q4 2025 at Summit Therapeutics, up from -$705000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $14.0 million in Q4 2025 and bottomed at -$4.3 million in Q2 2023.
  • Average Change in Accured Expenses over 5 years is $1.6 million, with a median of $1.1 million recorded in 2021.
  • The sharpest move saw Change in Accured Expenses crashed 1325.38% in 2021, then surged 5557.14% in 2023.
  • Year by year, Change in Accured Expenses stood at $2.1 million in 2021, then crashed by 101.7% to -$35000.0 in 2022, then soared by 5557.14% to $1.9 million in 2023, then increased by 19.32% to $2.3 million in 2024, then skyrocketed by 513.3% to $14.0 million in 2025.
  • Business Quant data shows Change in Accured Expenses for SMMT at $14.0 million in Q4 2025, -$705000.0 in Q3 2025, and $704000.0 in Q2 2025.